Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02873221 · ClinicalTrials.gov registry record · Phase 3
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,254
- Enrollment target
NCT02873221 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 1,254 participants.
The verdict
NCT02873221, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,254 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
Interventions
- DRUG Ubrogepant
- DRUG Usual Care
- DRUG Placebo-matching Ubrogepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,254 participants |
| Start Date | 2016-09-13 |
| Est. Completion | 2018-08-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02873221
The ClinicalTrials.gov registry entry for NCT02873221 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Ubrogepant is the first listed.
NCT02873221 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02873221 about?
NCT02873221 is a clinical study titled "An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine". This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
What is the current status of trial NCT02873221?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,254 participants. The study started on 2016-09-13. Estimated completion is 2018-08-02.
What interventions are being tested in trial NCT02873221?
The interventions under investigation include: Ubrogepant (DRUG), Usual Care (DRUG), Placebo-matching Ubrogepant (DRUG).
Who is sponsoring clinical trial NCT02873221?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.